Barinthus Biotherapeutics (BRNS) EBT (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported EBT of -$5.6 million for Q1 2026, up 71.8% on a YoY basis from -$3.2 million in Q1 2025, and up 50.27% quarter-over-quarter from -$11.2 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) EBT (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported EBT for 7 years, with the latest figure at -$5.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 71.8% year-over-year to -$5.6 million; the trailing twelve-month figure through Mar 2026 stood at -$52.5 million (up 19.66% YoY), and the FY2025 full-year result was -$66.6 million, down 8.83% from the prior year.
- EBT for Q1 2026 stood at -$5.6 million, up from -$11.2 million in the prior quarter.
- The five-year high for EBT was $14.8 million in Q2 2022, with the low at -$25.0 million in Q2 2023.
- Historically, EBT has averaged -$12.3 million across 5 years, with a median of -$15.6 million in 2024.
- Annual changes were most pronounced in 2022 — EBT surged 236.33% — and 2023, when it plunged 1195.21%.
- Barinthus Biotherapeutics' EBT stood at -$23.2 million in 2022, then increased by 21.88% to -$18.1 million in 2023, then decreased by 13.68% to -$20.6 million in 2024, then jumped by 45.79% to -$11.2 million in 2025, then soared by 50.27% to -$5.6 million in 2026.
- The last three EBT figures came in at -$5.6 million (Q1 2026), -$11.2 million (Q4 2025), and -$14.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | -5.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -11.16 Mn |
| Sep 30, 2025 | -14.64 Mn |
| Jun 30, 2025 | -21.15 Mn |
| Mar 31, 2025 | -19.68 Mn |
| Dec 31, 2024 | -20.59 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -16.95 Mn |
| Mar 31, 2024 | -15.56 Mn |
| Dec 31, 2023 | -18.11 Mn |
| Sep 30, 2023 | -14.71 Mn |
| Jun 30, 2023 | -24.96 Mn |
| Mar 31, 2023 | -18.74 Mn |
| Dec 31, 2022 | -23.18 Mn |
| Sep 30, 2022 | 7.55 Mn |
| Jun 30, 2022 | 14.77 Mn |
| Mar 31, 2022 | 1.71 Mn |
| Dec 31, 2021 | -16.69 Mn |
| Sep 30, 2021 | -5.54 Mn |
| Jun 30, 2021 | -16.85 Mn |